Dapagliflozin for heart failure according to body mass index: the DELIVER trial

Carly Adamson, Toru Kondo, Pardeep S. Jhund, +22

European Heart Journal

Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF

Carly Adamson, Kieran F. Docherty, Hiddo J.L. Heerspink, +18

Circulation

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index

Carly Adamson, Pardeep S. Jhund, Kieran F. Docherty, +21

European Journal of Heart Failure

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction

Leanne Mooney, Colette E. Jackson, Carly Adamson, +7

Circulation Heart Failure

Impact of Comorbidities on Health Status Measured Using the Kansas City Cardiomyopathy Questionnaire in Patients with Heart Failure with Reduced and Preserved Ejection Fraction

Mingming Yang, Toru Kondo, Carly Adamson, +13

European Journal of Heart Failure

Liver tests and outcomes in heart failure with reduced ejection fraction: findings from <scp>DAPA‐HF</scp>

Carly Adamson, Lorna M. Cowan, Rudolf A. de Boer, +19

European Journal of Heart Failure

Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction

James P. Curtain, Carly Adamson, Toru Kondo, +14

European Heart Journal

IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction

Carly Adamson, Paul Welsh, Kieran F. Docherty, +21

JACC Heart Failure

Neuropeptide Y is Elevated in Heart Failure and is an Independent Predictor of Outcomes

Kirsty McDowell, Carly Adamson, Colette E. Jackson, +6

European Journal of Heart Failure

Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan

James P. Curtain, Carly Adamson, Kieran F. Docherty, +10

JACC Heart Failure